Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological University Anantapur (JNTUA), Ananthapuramu, India.
Chemical Engineering, JNTUA College of Engineering (Autonomous), Jawaharlal Nehru Technological University Anantapur (JNTUA), Ananthapuramu, India.
Drug Dev Ind Pharm. 2024 Apr;50(4):320-330. doi: 10.1080/03639045.2024.2327466. Epub 2024 Mar 15.
The purpose of this study was to formulate, optimize Ozenoxacin topical nano-emulsion using factorial design followed by to prepare and evaluate nano-emulgel using validated release testing (IVRT) technique for determination of Ozenoxacin release rate along with permeation testing (EVPT).Significance: Nano-emulgel is a proven delivery system for poorly soluble substances works by enhancing the solubility and bioavailability. Factorial design provides a systematic and efficient means to study the effect of multiple factors on responses. IVRT is an USP compendia technique utilized for performance analysis of semi-solid formulations.
Nano-emulsion formulation optimization was done with factorial design, evaluated for globule size and % entrapment efficiency (EE). Nano-emulgels were characterized for assay, organic impurities, rheological behavior, IVRT, EVPT, and skin retention studies. IVRT validation was executed using vertical diffusion cells (VDCs).
Ozenoxacin nano-emulsion was optimized with 1:1 ratio of Oil: S, 3:1 ratio of Surfactant:Co-Surfactant, and 15000 RPM of homogenization speed which resulted 414.6 ± 5.2 nm globule size and 92.8 ± 2.1% entrapment efficiency. Results confirmed that IVRT and Reversed Phase - High Performance Liquid Chromatographic techniques were validated as per regulatory guidelines. , drug release, and skin retention from the optimized nano-emulgel formulation was comparatively higher (∼1.5 times) than that from the innovator (OZANEX) formulation.
Based on these results, Ozenoxacin nano-emulgel can be considered an effective alternative and was found to be stable at 40 °C/75% RH and 30 °C/75% RH storage condition for 6 months.
本研究的目的是通过使用因子设计来制备和优化奥扎诺星局部纳米乳,随后使用经过验证的释放测试(IVRT)技术来制备和评估纳米乳凝胶,以确定奥扎诺星的释放速率以及渗透测试(EVPT)。意义:纳米乳凝胶是一种已被证实的用于传递难溶性物质的给药系统,通过提高溶解度和生物利用度来发挥作用。因子设计提供了一种系统且有效的方法来研究多个因素对响应的影响。IVRT 是 USP 典中的一种技术,用于分析半固体制剂的性能。
通过因子设计对纳米乳制剂进行优化,评价其粒径和包封效率(EE)。纳米乳凝胶的特性包括含量测定、有机杂质、流变行为、IVRT、EVPT 和皮肤滞留研究。IVRT 验证使用垂直扩散池(VDC)进行。
奥扎诺星纳米乳的最佳配方为油:表面活性剂(S)比为 1:1,表面活性剂:助表面活性剂比为 3:1,均质速度为 15000rpm,得到的粒径为 414.6±5.2nm,包封效率为 92.8±2.1%。结果证实,IVRT 和反相-高效液相色谱技术均符合法规指南的要求。从优化的纳米乳凝胶制剂中释放药物的速度、皮肤滞留率以及从优化的纳米乳凝胶制剂中释放药物的速度和皮肤滞留率均高于(约 1.5 倍)创新制剂(奥扎诺星)的制剂。
基于这些结果,奥扎诺星纳米乳凝胶可以被认为是一种有效的替代制剂,并且在 40°C/75%RH 和 30°C/75%RH 储存条件下稳定,有效期为 6 个月。